Evicenter
P&T meetings

Emcitate (tiratricol)

MCT8 deficiency

Last updated
78 sources

Product information and disease descriptionProduct descriptionProduct information

Average sales price and wholesale acquisition cost

3 evidence topics · 2 sources

U.S. average sales price and wholesale acquisition cost

No evidence found.

Product pricing, Germany: pharmacy sales price and statutory rebates
Packaging sizeCosts (pharmacy sales price)Rebate Section 130 SGB VRebate Section 130a SGB VCosts after deduction of statutory rebatesPrice list revision
“60 TOS”“€ 15,415.68”“€ 1.77”“€ 877.10”“€ 14,536.81”“15 August 2025”
Product pricing, Germany: dose range used for annual treatment costs

“Adjustment of the maintenance dose of tiratricol is patient-individual, depending on the thyroid levels in the serum and body weight. Against this background, the decision is based on a cost range.” (opens the source at this quote in a new tab)

“The starting dose of 175μg/day for children weighing less than 10 kg is used as the lower limit.” (opens the source at this quote in a new tab)

“The product information specifies a maximum dosage of 50 μg/day/kg body weight (BW) for subjects weighing more than 60 kg.” (opens the source at this quote in a new tab)

Limit of cost rangeDose per treatment dayConsumption by potency per treatment dayTreatment days per patient per yearAverage annual consumption by potency
Lower limit“175 μg”“0.5 x 350 μg”“365.0”“182.5 x 350 μg”
Upper limit“3850 μg”“11 x 350 μg”“365.0”“4015 x 350 μg”
German reimbursement negotiations: subsequent price agreement

“The Emcitate price negotiations within the German reimbursement process (AMNOG) concluded in Q2 2026 and are valid from August 1” (opens the source at this quote in a new tab)